Morningstar does not publish an Analyst Report for . Click here to view our coverage.
Morningstar analysts cover more than 1,900 stocks. Below is a sample Analyst Report for another
stock, QGEN.
After capturing the leading share of the sample preparation market, Qiagen now seeks to establish a greater footprint in the assay realm, particularly with molecular diagnostics. Competition will provide a stiff challenge, but Qiagen has the tools to Read more
Bulls Say
Qiagen offers its whole range of low- to high-throughput instruments to all its customer segments, giving customers a wide range of choices and capabilities.
Government stimulus money will likely boost academic research budgets in 2010, which could positively affect Qiagen's product sales.
Qiagen's companion diagnostic tests may enjoy high growth rates as personalized medicine gains more focus amongst researchers, doctors, and payors. Read more
Bears Say
The HPV test still needs to surmount many adoption barriers and may not gain significant market share.
Qiagen's diagnostics offering only focuses on molecular testing. Customers may prefer to deal with only one supplier, such as Roche, which offers a broader range of diagnostic tests.
Researchers who use their own home-brew sample preparation may never adopt Qiagen kits, and future growth in this segment may slow. Read more
Strategy
Qiagen seeks to establish a greater footprint in molecular diagnostics and applied testing. The firm especially hopes to increase awareness and usage of HPV test kits from recently acquired Digene. On Read more
Management
We think Qiagen has fair stewards at its helm and give the firm a C Stewardship Grade. CEO Peer Schatz has led the firm for five years. He previously held the CFO and managing director positions at Qiagen, giving him ample executive experience. Co-founder Read more
Profile
Qiagen offers leading sample and assay technology to collect, purify, detect, and analyze DNA, RNA, and proteins. The firm sells these products in molecular diagnostic, Read more
Dodge & Cox: Health Care Now More Attractive Watch more
View all of our analyst reports with a free trial to Morningstar.com Premium.